www.engadget.com

2023 was a big year for CRISPR-based gene editing but challenges remain

2023 was an important year for patients with sickle cell disease. The FDA approved Vertex’s “Casgevy,” a CRISPR-based therapy for the treatment of sickle cell disease marking it as the first genetical